Introduction
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease (1). It is a devastating progressive neurological disorder characterized by the loss of dopamine (DA) neurons in the substantia nigra pars compacta (SNc) (2) (3) (4) . These neurons project to the striatum and release DA to postsynaptic targets that control motor behavior. Thus, loss of these SNc DA neurons leads to the hallmark motor deficits associated with PD: bradykinesia, rigidity, and resting tremors. Identified genetic mutations account for 5%-9% of the risk of PD (1) . A primary risk factor for PD is aging (5) , with sporadic PD afflicting 2% of the population over 60 years of age and 15% over 85. Despite decades of research, the reason for the greater sensitivity of SNc DA neurons to degeneration and why their loss is strongly associated with aging in PD is unknown.
α-Synuclein aggregates in Lewy bodies are believed to play a crucial role in PD pathogenesis. In support of this hypothesis, human α-synuclein gene (SNCA) mutations as well as SNCA gene duplication dramatically increase the risk of early-onset PD (6) (7) (8) (9) . Furthermore, increased α-synuclein protein expression is observed in the aging human SNc (10, 11) . Various mouse studies also speak to the critical role of α-synuclein in PD pathogenesis. Mice expressing mutant human α-synuclein (A53T) in CNS neurons are prone to profound neurodegeneration with characteristic histopathological features of PD as well as motor dysfunction (12) . α-Synucleinopathy and motor defects are also observed in mice expressing WT human α-synuclein (13). Finally, striatal administration of synthetic misfolded mouse α-synuclein fibrils induces
Parkinson's disease (PD) is primarily a nonfamilial, age-related disorder caused by α-synuclein accumulation and the progressive loss of dopamine neurons in the substantia nigra pars compacta (SNc). GPCR-cAMP signaling has been linked to a reduction in human PD incidence and α-synuclein expression. Neuronal cAMP levels are controlled by GPCRs coupled to G s or G i/o , which increase or decrease cAMP, respectively. Regulator of G protein signaling 6 (RGS6) powerfully inhibits G i/o signaling. Therefore, we hypothesized that RGS6 suppresses D 2 autoreceptor-G i/o signaling in SNc dopamine neurons promoting neuronal survival and reducing α-synuclein expression. Here, we provide potentially novel evidence that RGS6 critically suppresses late-age-onset SNc dopamine neuron loss and α-synuclein accumulation. RGS6 is restrictively expressed in human SNc dopamine neurons and, despite their loss in PD, all surviving neurons express RGS6. RGS6 -/-mice exhibit hyperactive D 2 autoreceptors with reduced cAMP signaling in SNc dopamine neurons. Importantly, RGS6
-/-mice recapitulate key sporadic PD hallmarks, including SNc dopamine neuron loss, reduced nigrostriatal dopamine, motor deficits, and α-synuclein accumulation. To our knowledge, Rgs6 is the only gene whose loss phenocopies these features of human PD. Therefore, RGS6 is a key regulator of D 2 R-G i/o signaling in SNc dopamine neurons, protecting against PD neurodegeneration and α-synuclein accumulation.
SNc DA neuron degeneration and motor defects demonstrating cell-to-cell transmission of pathological α-synuclein in anatomically connected regions (14) . Thus, having too much α-synuclein or its mutated forms can produce PD-like pathology in mice.
Recent studies have suggested a possible link between GPCR signaling, PD-associated neurodegeneration, and pathological α-synuclein accumulation. Mittal et al. (15) reported that β-agonists dramatically reduce both α-synuclein expression and the incidence of human PD as well as inhibit MPTP-induced SNc DA neuron loss in mice. These findings are intriguing given our recent discovery that regulator of G protein signaling 6 (RGS6) is required for SNc DA neuron survival in adult mice (16) . RGS6 is a member of the RGS protein family, which is a critical modulator of GPCR signaling. Specifically, RGS proteins determine the magnitude and duration of GPCR signaling through their role as GTPase-activating proteins, allowing them to inactivate heterotrimeric G protein Gα subunits (17) (18) (19) . In mice, we found that RGS6 is expressed in the same subset of SNc DA neurons that are lost in PD and that RGS6 -/-mice consistently display SNc DA neuron degeneration beginning around 9 months. Furthermore, the expression of several DA D 2 autoreceptor (D 2 R) targets is altered in SNc DA neurons of RGS6 -/-mice (16), suggesting that RGS6-mediated attenuation of D 2 R-G i/o signaling may be neuroprotective. Given that both β-agonists and RGS6 function to promote cAMP signaling by stimulating G s and inhibiting G i/o (20, 21) , respectively, we hypothesized that RGS6 may promote SNc DA neuron survival by repressing pathological α-synuclein accumulation and resultant neurodegeneration.
Here, we demonstrate that RGS6 plays a critical role in preventing late-age-onset PD-associated neurodegeneration and pathological α-synuclein accumulation. First, we show that RGS6 is expressed in human SNc DA neurons that are lost with PD, consistent with what we have seen in mice. Second, RGS6 loss in mice results in a significant age-dependent reduction in SNc and striatal DA as well as impaired dopaminergic neurotransmission causing stereotypical PD motor deficits. Third, we show that RGS6 is absolutely required for regulation of D 2 R function, promoting proper DA synthesis and release, as well as SNc DA neuron survival. Finally, we provide evidence demonstrating that RGS6 functions to prevent pathological α-synuclein accumulation in aged mice. Together, these data identify RGS6 as a potentially novel and critical repressor of the D 2 R signaling involved in preventing both age-dependent PD-associated pathological α-synuclein expression and SNc DA neuron degeneration.
Results

RGS6 is expressed in human SNc DA neurons that are lost in PD and in aged RGS6
-/-mice. Our previous work in mice indicates that in the SNc, RGS6 is exclusively expressed in DA neurons (16) . To determine whether this pattern of RGS6 expression is preserved in the human SNc, we performed an immunohistochemical analysis of RGS6 and tyrosine hydroxylase (TH) expression in human midbrain sections. Representative images of the paraffin-embedded midbrain tissue blocks containing the pigmented SNc DA neurons can be seen in Figure  1A . Immunohistochemical analysis of both control and PD specimens revealed that, as in mice, RGS6 is expressed in all DA (TH + ) neurons within the human SNc. Furthermore, an unbiased stereological analysis revealed that when compared with control SNc tissues, there is a significant 73% reduction in the density of both TH + and RGS6 + neurons in the SNc of patients with PD ( Figure 1A ). This finding is similar to the 79% loss of TH + neurons in PD midbrains originally reported by Damier et al. (22) . Thus, consistent with its proposed need for SNc DA neuron survival, RGS6 is expressed in all SNc DA neurons in humans, and all surviving neurons in patients with PD express RGS6. Immunohistochemical and unbiased stereological analysis of the mouse SNc revealed a 52% reduction in TH + neuron density in aged, 12-month-old RGS6
-/-mice compared with RGS6 +/+ mice ( Figure 1B) . Thus, aged RGS6 -/-mice exhibit robust SNc DA neuron loss, as seen in human PD. Further immunohistochemical analysis revealed that RGS6 is not only present in SNc DA neuron cell bodies, but is also expressed in DA terminals in the dorsal striatum (Supplemental Figure  1 ; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.126769DS1).
Aged RGS6 -/-mice exhibit altered DA homeostasis and impaired motor performance. RGS6 is expressed in SNc DA neurons and despite their loss in PD, all surviving neurons express RGS6. In addition, RGS6 deficiency in aged mice leads to loss of SNc DA neurons (Figure 1 ). These data suggest that RGS6 plays a crucial role in the function of these neurons and that losing RGS6 could result in altered DA content as well as impaired motor function due to loss of SNc DA neurons. To test this theory, we measured DA and its metabolites in the SNc and striatum of 3-, 9- Figure 2, A and B) . Remarkably, by 12 months of age, there was ≥50% reduction in DA content within the SNc and striatum of RGS6 -/-mice. Interestingly, DA levels were reduced in the striatum of RGS6 -/-mice by 3 months, before any significant loss was detected in the SNc and before marked DA neuron degeneration occurs (16) . This finding suggests that the loss of DA content in the striatum at 3 months is directly related to the ability of RGS6 to regulate DA synthesis and potentially its release, at the SNc dopaminergic axon terminal, where we found RGS6 is expressed robustly (Supplemental Figure 1) . Further supporting a critical role of RGS6 in SNc DA handling, there was a significant increase in the 3,4-dihydroxyphenylacetic acid (DOPAC)/DA ratio in both the striatum and SNc of 12-month-old RGS6 -/-mice relative to agematched RGS6 +/+ mice ( Figure 2 , C and D). This is interesting as DOPAC, a major DA metabolite (23) , has been shown to be increased relative to DA in the midbrains of humans with PD and is also associated with impaired vesicular DA uptake (24) . Because DA in synaptic vesicles does not undergo metabolism to DOPAC, this observation suggests that RGS6 loss leads to DA accumulation in the cytoplasm and, given the overall decrease in DA content within the striatum, reduced synaptic DA. Taken together, these data provide potentially novel evidence of an age-dependent role for RGS6 in maintaining proper SNc DA homeostasis in mice. SNc DA neurons powerfully regulate movement. As such, we hypothesized that the degeneration of SNc DA neurons in aged RGS6 -/-mice would cause PD-associated motor deficits, which we investigated via a variety of assays. First, we found that 12-month-old RGS6 -/-mice have impaired rotarod performance, exemplified by a significantly decreased latency to fall, in comparison with age-matched RGS6 +/+ controls ( Figure  3A ). Previously, we showed that young (3-month-old) RGS6 -/-mice had GABA B R-dependent rotarod and forelimb gait deficits due to excessive cerebellar GABA signaling that were reversed by a GABA B R antagonist. However, the impaired rotarod performance of aged (12-month-old) RGS6 -/-mice was not reversed by GAB-A B R antagonist SCH-50911 but rather was partially reversed by L-3,4-dihydroxyphenylalanine (L-DOPA), confirming that the motor deficits seen in 12-month-old RGS6 -/-mice are the direct result of reduced dopaminergic signaling ( Figure 3A ). Aged RGS6 -/-animals also had deficits in open-field locomotion ( Figure 3B ), in contrast to increased open-field activity of 3-month-old RGS6 -/-mice compared with RGS6 +/+ controls (ref. 25 ; see below). To further quantify movement, we turned to DigiGait, which measures gait dynamics using an automated treadmill gait test. Aged RGS6 -/-mice showed a decrease in hind limb stride length and an increase in hind limb stride frequency that could be partially reversed, once again, through treatment with L-DOPA, but not SCH-50911 ( Figure 3 , C and D). Interestingly, the movement disorders reported here for RGS6 -/-mice are seen in aged but not young mice (25, 26) and are characteristic of other mouse models of PD (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) . Taken together, these data demonstrate that RGS6 -/-mice not only display age-dependent loss of SNc DA neurons but also the accompanying PD-like motor dysfunction.
RGS6 loss leads to increased D 2 R signaling in SNc DA neurons. G i/o -coupled D 2 Rs negatively regulate DA neurotransmission by inhibiting DA synthesis and release while concomitantly promoting DA reuptake into the presynaptic terminal ( [37] [38] [39] [40] . Specifically, D 2 R activation inhibits TH phosphorylation and activation The SNc DOPAC/DA ratio was also significantly increased in RGS6 -/-mice relative to RGS6 +/+ animals at 12 months. As seen in the striatal DOPAC/DA ratio, a significant effect of age was also observed in the SNc [F (1,32) = 4.91, P = 0.034]. Data were analyzed using a 2-way ANOVA with Fisher LDS post hoc adjustment. Data are presented as mean ± SEM (N = [5] [6] [7] +/+ mice and 6-9 RGS6 -/-mice). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.
through inhibition of adenylyl cyclase, inhibits the probability of DA release by activating K + and inhibiting Ca 2+ channels, and increases the plasma membrane expression of dopamine transporter (DAT). Given our findings that RGS6 plays a critical role in negatively regulating signaling by various G i/o -coupled receptors in vivo (25, 26, 41) and that degeneration of SNc DA neurons in aged RGS6 -/-mice is associated with increased DAT expression (16), we hypothesized that RGS6 suppresses D 2 R-G i/o -mediated inhibition of DA synthesis and release. To test this hypothesis, we evaluated the effects of the D 2 R agonist quinpirole on the suppression of locomotion in 3-month-old RGS6 +/+ and RGS6 -/-mice. Young mice were used in this study to avoid the late-age-onset SNc neurodegeneration resulting from RGS6 deficiency. Numerous studies have shown that quinpirole suppression of locomotion in mice is due to its presynaptic actions on activating the D 2 R in the nigrostriatal pathway (42) (43) (44) (45) . These studies demonstrated that mice lacking presynaptic but not postsynaptic D 2 Rs lose quinpirole suppression of locomotion as well as quinpirole inhibition of firing and DA release, both measures of presynaptic D 2 R function, from SNc DA neurons. As shown in Figure 4 , although 3-month-old RGS6 -/-mice have a modest increase in locomotor activity compared with RGS6 +/+ mice as we previously reported (25) , they are significantly more sensitive to quinpirole-locomotor suppression as measured by total distance traveled ( Figure 4A ), open-field velocity ( Figure 4B ), and movement to center ( Figure 4C ). Both the overall effect of quinpirole on these locomotor measures and their change from saline-treated mice was significantly greater (50%-100% greater) in RGS6
-/-mice compared with RGS6 +/+ mice. For example, quinpirole reduced the distance traveled, velocity, and moving to center by 79%, 79%, and 59%, respectively, +/+ and RGS6 -/-mice/treatment group). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
in RGS6 -/-mice and by 52%, 52%, and 29%, respectively in RGS6 +/+ mice. These findings provide in vivo evidence that RGS6 functions to suppress D 2 R-mediated G i/o signaling in DA neurons.
RGS6 loss leads to aberrant α-synuclein accumulation. Given the ability of RGS6 to promote cAMP accumulation in the SNc through its inhibition of G i/o (20, 21) , we hypothesized that RGS6 may suppress α-synuclein expression as other cAMP-elevating agents, such as β-agonists (15) have been recently reported to do. To test our hypothesis, we performed an immunohistochemical analysis of α-synuclein and TH expression in the SNc of 3-, 12-, and 18-month-old RGS6 +/+ and RGS6 -/-mice. As shown in Figure 5 , A and B, RGS6 -/-mice exhibited not only age-dependent SNc DA neuron loss at 12 and 18 months, but also a concomitant and dramatic increase in α-synuclein expression compared with RGS6 +/+ mice or 3-month-old mice of either genotype. The increase in α-synuclein expression was more pronounced at 18 months than 12 months. Interestingly, and unlike what was seen in 3-month-old mice of either genotype as well as aged RGS6 +/+ mice, most of the α-synuclein in the SNc of 12-and 18-month-old RGS6 -/-mice was not colocalized with DA neurons and was instead found extracellularly ( Figure 5C ). This finding was confirmed through quantitative comparison of the relative localization of α-synuclein with TH, an intracellular marker of DA neurons. Both intracellular and extracellular oligomeric forms of α-synuclein are linked to PD pathophysiology ( [46] [47] [48] . Following SDS PAGE and immunoblotting, these α-synuclein oligomers appear as distinct higher-molecular-weight forms of the protein or protein smears. In brains or spinal cords derived from transgenic mice expressing PD-causing human α-synuclein mutants or those with intracerebral injections of α-synuclein fibrils, α-synuclein oligomers are found in nonionic detergent-insoluble, SDS-or urea-soluble fractions (12, 14, 49, 50) . Alternatively, these oligomeric forms of α-synuclein can also be visualized in whole-brain homogenates derived from transgenic mice expressing mutant human α-synuclein and leucine-rich repeat kinase 2-deficient mice (51, 52) . Utilizing the whole RIPA homogenate method of α-synuclein detection described by Giaime et al. (52) , in Figure 5 , D and E, we show that there is significantly greater oligomeric (higher-molecular-weight [HMW]) α-synuclein immunoreactivity in SNc punches derived from 12-month-old RGS6 -/-mice relative to RGS6 +/+ controls. These data are consistent with our immunohistochemical findings in Figure 5 , A-C. Together, these findings show that the late-age-onset dopaminergic neurodegeneration observed in the SNc of RGS6 -/-mice is accompanied by aberrant α-synuclein accumulation.
cAMP signaling is attenuated in RGS6 -/-SNc DA neurons. We sought to investigate whether RGS6 loss leads to decreased cAMP-PKA signaling in SNc DA neurons. This possibility is suggested both by our finding that RGS6 loss increases G i/o -coupled D 2 R activity in SNc DA neurons (Figure 4) as well as our discovery that RGS6 loss causes increased SNc α-synuclein accumulation ( Figure 5 ) -the latter suppressed by cAMP-elevating β-agonists (15). As predicted, the data shown in Figure 6 , A and B, demonstrate that RGS6 loss leads to a significant reduction in PKA activity in SNc DA neurons by 12 months, as measured -/-mice). *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.
using an antibody recognizing the phosphorylated PKA substrate motif. Similarly, TH phosphorylation at S40 mediated by cAMP-PKA, was also significantly decreased in RGS6 -/-mice at 12 months ( Figure 6 , C and D). Importantly, this reduction in pS40 TH levels in 12-month-old RGS6 -/-mice could be reversed through treatment of mice with either the D 2 R antagonist raclopride (3 mg/kg) or the activator of adenylyl cyclase forskolin (3.75 mg/kg; Figure 6 , E and F). These results confirm that the canonical function of RGS6 to inhibit D 2 R-G i/o signaling promotes cAMP-PKA signaling in SNc DA neurons.
In keeping with its role in modulating D 2 R-G i/o signaling in SNc DA neurons, RGS6 exhibits a predominant membrane/cytosolic localization in these neurons (Supplemental Figure 2) . Loss of RGS6 did not alter the expression of other R7 members in the SNc or striatum (Supplemental Figure 3) .
Discussion
The results depicted herein show that RGS6-deficient mice remarkably recapitulated the late-age-onset loss of SNc DA neurons (ref. 16 and Figure 1 ), DA loss (Figure 2 ), motor dysfunction (Figure 3) , and aberrant expression of α-synuclein ( Figure 5 ) characteristic of the majority of patients with PD. To our knowledge, 
(D and E) Western blotting (D) and quantification (E) of α-synuclein collected from SNc tissues of 12-month-old RGS6
+/+ and RGS6 -/-mice (n = 4 mice/group) using the Syn-1 antibody, with GAPDH as a loading control. Increased expression of α-synuclein is characterized by an aberrant smearing pattern, as observed in RGS6 -/-but not WT mice. Data were analyzed using either 1-(E) or 2-way (B and C) ANOVA with Fisher LSD post hoc analysis. Data are presented as mean ± SEM. **P ≤ 0.01, ***P ≤ 0.001.
RGS6 is the only known gene whose loss phenocopies these features of sporadic PD, thus identifying RGS6 as a disease-relevant target for PD treatment. In addition, we show that RGS6 is a key negative modulator of G i/o signaling in SNc DA neurons, with its loss provoking enhanced D 2 R activity and a subsequent reduction in cAMP-PKA signaling (Figures 4 and 6) . The ability of RGS6 to promote cAMP-PKA signaling may contribute to its neuroprotective functions and its ability to suppress α-synuclein expression. cAMP-PKA signaling has been shown to be neuroprotective in mouse models of PD ( [53] [54] [55] , and cAMP-elevating β-agonists both reduce the incidence of human PD and suppress SNc α-synuclein expression in humans and mice (15) . Furthermore, RGS6 is expressed in human SNc DA neurons and is lost with these DA neurons in patients with PD. Importantly, all surviving SNc DA neurons in patients with PD express RGS6. Together, these findings have guided us to the hypothesis that RGS6, through its canonical function in GPCR signaling (in this case, D 2 R signaling) is required for SNc DA neuron survival and function (Figure 7) . This insight has the potential to spur a new direction of research for the understanding of PD and its treatment. -/-mice treated with vehicle (saline), forskolin, or raclopride as described in (D). A significant effect of treatment was observed (n = 4-5 mice/treatment group; F crit = 6.47; P = 0.014). Data were analyzed using either 1-(E and F) or 2-way (B) ANOVA analyses. Data are presented as mean ± SEM. *P ≤ 0.05, **P ≤ 0.01.
The particular relevance of the RGS6
-/-mouse for human PD lies not only in its ability to recapitulate the stereotypical late-age-onset death of SNc DA neurons, but also in its ability to reproduce deficits in DA synthesis, release, and catabolism that have been described in other animal models (56, 57) . We found that concomitant with SNc DA neuron degeneration in RGS6 -/-mice, there is a significant age-dependent reduction in DA content within the SNc and striatum (Figure 2 ). This reduction in striatal DA content is also seen in mouse models where Gβ 5 , an atypical Gβ subunit that stabilizes R7 family members (RGS6, 7, 9, and 11; refs. 20, 58, 59), is genetically ablated (60) .
A point of interest in the RGS6 -/-mouse model is that the significant reduction in DA begins in the striatum as early as 3 months (Figure 2A ), well before neurodegeneration is seen in these animals (16) . These data suggest that the reduction in DA content is not solely due to neuronal loss, but that RGS6 itself is potentially responsible for proper DA synthesis, catabolism, release, and reuptake in the nigrostriatal pathway. This supposition is consistent with our previous findings demonstrating that RGS6-deficient SNc neurons display altered expression of several proteins that are required for DA synthesis, packaging, and uptake (16) . Specifically, we found that RGS6-deficient SNc neurons have reduced levels of TH and vesicular monoamine transporter 2 (Vmat2) and an increase in DAT expression (16) . Thus, despite having an impaired ability to synthesize DA (low TH) these RGS6-deficient neurons would be predicted to have abnormally high levels of cytosolic DA due to their inability to properly package the DA into vesicles (low Vmat2) and an accelerated rate of DA reuptake from the synaptic cleft (high DAT; refs. 61). In agreement with this prediction, we demonstrate that at 12 months, the DOPAC/DA ratio was significantly increased in both the striatum and SNc of RGS6 -/-mice ( Figure 2, C and D) . Because DA metabolism occurs in the cytoplasm, these data demonstrate an impaired ability of RGS6-deficient SNc DA neurons to properly manage DA packaging and transmission. Our results recapitulate a similar increase in the DOPAC/DA ratio seen not only in other animal PD models but also in human PD patient samples (24, (62) (63) (64) (65) . Additionally, alterations in the expression of VMAT2, DAT, and ALDH1A within the SNc of RGS6 -/-mice may reveal the toxic mechanism responsible for SNc DA neuron degeneration, as previous studies using transgenic mice have demonstrated that while VMAT2 and ALDH1A protect SNc DA neurons and oppose PD, increases in DAT expression provoke SNc neurodegeneration (66) (67) (68) (69) (70) (71) . Exactly how alteration in these factors lead to neurodegeneration is uncertain, but it is possible that the dysfunction in the transportation, storage, and catabolism of DA caused by their altered expression may contribute to an accumulation of cytotoxic DA metabolites, such as 3,4-dihydroxyphenylacetaldehyde in the cytosol (Figure 7 and refs. 72-76) . The ability of RGS6 to modulate the expression of numerous proteins required for proper DA synthesis and signaling is likely related to its ability to negatively regulate G i/o -coupled D 2 Rs present in SNc DA neurons. In support of this hypothesis, previous studies have shown that selective genetic ablation of D 2 Rs within the mouse nigrostriatal pathway is associated with an increase in DA synthesis and release as well as increased locomotion (42) . In addition, we previously showed (16) that D 2 R expression was unaltered in SNc DA neurons lacking RGS6, despite altered expression of DAT and VMAT2, proteins regulated by the D 2 R ( [37] [38] [39] [40] [77] [78] [79] . These findings suggest that altered D 2 R signaling in the RGS6 -/-mouse is likely due to loss of RGS6-mediated inhibition of G i/o protein signaling. In agreement with these findings, quinpirole suppression of locomotion, which is mediated exclusively by D 2 Rs ( [42] [43] [44] [45] , is significantly greater in RGS6 -/-than RGS6 +/+ mice ( Figure 4 ). These data provide evidence that RGS6 regulates D 2 R activity in the presynaptic terminal within the nigrostriatal pathway, not the striatal postsynaptic D 2 Rs. Importantly, increased D 2 R activity in RGS6 -/-mice could explain the reduction in striatal DA seen in young mice (3 months; Figure 2 ). Direct support of this possibility was provided by analysis of effects of RGS6 deficiency on pS40 TH levels in SNc DA neurons. It is well known that TH is activated by PKA-mediated phosphorylation on S40, known to be diminished by activation of presynaptic D 2 Rs (43, 80) . We showed that 12-month-old RGS6 -/-mice exhibit a significant reduction in levels of pS40 TH, which was rescued by inhibiting presynaptic D 2 Rs or by elevating cAMP to oppose D 2 R-G i/o -mediated suppression of cAMP. These findings show that RGS6 functions to negatively regulate D 2 R-G i/o signaling in SNc DA neurons and support our behavioral studies in which RGS6 -/-mice had significantly increased suppression of locomotion by quinpirole. Further, these results support our hypothesis that RGS6 may protect against PD pathogenesis through its ability to block D 2 R-mediated inhibition of DA synthesis and signaling (Figure 7) , an inhibition which can be neurotoxic. For example, cytosolic DA and its metabolites are neurotoxic (66, 69, 72) and increased expression of DAT provokes SNc neuronal cell death (71) .
Together, our data portray a critical role for RGS6 in proper nigrostriatal DA synthesis and neurotransmission, required for normal motor control. Our data are consistent with several PD studies, including those using rodent models of neurochemical lesions (27, 28, 31, 32, 36) , transgenic rodent models of PD (29, 30, (33) (34) (35) , and studies of human patients with PD (81). Interestingly, both deficits in motor coordination and synchrony seen in RGS6 -/-mice were partially reversed through L-DOPA treatment, but not through treatment with a GABA B R antagonist (Figure 3 ). These data stand in contrast to our previous report that motor coordination deficits measured in 3-month-old RGS6 -/-mice were related to disinhibition of the GABA B R (26) . Therefore, the results presented in this article conclusively demonstrate that RGS6 loss in aged animals leads to increased D 2 R activity and reduced DA neurotransmission within the nigrostriatal pathway manifesting as a PD-associated impairment in motor performance. Interestingly, another R7 family member, RGS9, has also been implicated as a key regulator of nigrostriatal function (82) (83) (84) . However, analysis of RGS9 expression reveals that instead of being expressed in SNc DA neurons, it is expressed and upregulated in striatal neurons during human PD (82) . Similar to RGS6 -/-mice, genetic ablation of RGS9-2 leads to increased striatal neuron D 2 R activity and PD-like motor deficits (84) (85) (86) . RGS6 loss had no effects on levels of expression of RGS9, which is expressed in striatum but not SNc, or other R7 family members in the SNc or striatum by Western blotting (Supplemental Figure 3) .
The ability of RGS6 to promote cAMP-PKA signaling likely contributes to both its neuroprotective functions as well as its ability to suppress aberrant α-synuclein accumulation in the SNc. RGS6, through inhibition of G i/o , is a predominant neuronal modulator of adenylyl cyclase activation and cAMP signaling (20, 21, 25, 26, 41) . Our finding that RGS6 inhibits G i/o -linked D 2 R signaling in SNc DA neurons is significant, as cAMP-PKA signaling has been linked to SNc neuron survival and hence PD prevention. First, cAMP-elevating β 2 agonists reduce α-synuclein expression, decrease the risk of human PD, and protect against PD in mice and human cells (15) . Second, inhibition of mitochondrial fission by PKA-mediated dynamin-related protein 1 phosphorylation is neuroprotective in mouse PD and cell culture models (53) (54) (55) . In agreement with these previous reports, we observed elevated SNc α-synuclein protein expression in 12-and 18-month-old RGS6 -/-mice relative to RGS6 +/+ controls. The aberrant elevation in α-synuclein expression in the SNc of RGS6 -/-mice was accompanied by a transition in α-synuclein expression patterns from largely intracellular, as seen in RGS6 +/+ mice, to largely extracellular ( Figure 5 ). These data may either reflect a change in α-synuclein handling in the SNc of RGS6 -/-mice or the persistence of previously intracellular α-synuclein aggregates after DA neurons have degenerated. These data are intriguing, as the presence of extracellular α-synuclein aggregates has been well-documented in various PD models, and it has also been shown that these extracellular aggregates may play an important role in PD pathology, as they can be transmitted to other neurons, glia, and brain regions (46) (47) (48) . Together, our data provide evidence that RGS6 increases cAMP in SNc DA neurons to promote proper neuronal function/survival as well as suppress cytotoxic α-synuclein accumulation. It will be important to determine the role of α-synuclein in neurodegeneration in RGS6-deficient mice and to perform future rescue studies with viral expression of RGS6.
Based upon our findings, we propose that RGS6 protects against PD pathogenesis by suppressing the D 2 R-G i/o signaling axis in SNc DA neurons, ensuring normal DA synthesis and release while preventing accumulation of cytotoxic DA metabolites and pathological α-synuclein (Figure 7) . We believe this work positions RGS6 as a potentially novel avenue for therapeutic strategies in Parkinson's neurodegeneration.
Methods
Animals. RGS6-knockout (RGS6 -/-) mice (129/Sv × C57BL6 background) were described previously (41) . RGS6 -/-mice were backcrossed [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] times with the C57BL/6J mouse strain. Three-, nine-, twelve-, and eighteen-month-old RGS6 +/+ and RGS6 -/-mice of both sexes were used. Mice were housed with a continuous supply of food and water in a room maintained at 22 ο C, with a relative humidity of 20%-30% and a 12-hour/12-hour light/dark cycle. Behavioral studies were performed between 10 am and 4 pm.
Neurochemical analysis. RGS6 +/+ and RGS6 -/-mice were euthanized at 3, 9, and 12 months of age. SNc and striatum were rapidly dissected and stored at -80°C. All samples were sent to the Vanderbilt Neurochemistry core for dopamine/metabolite extraction and HPLC analysis.
Behavioral analyses. All behavioral studies were performed using male mice. Behavioral analyses were performed in RGS6 +/+ and RGS6 -/-animals that were (a) 12 months of age (model of age-onset PD) and received i.p. injections of saline, L-DOPA (25 mg/kg; Tocris Biosciences), or SCH-50911 (30 mg/kg: Tocris Biosciences) or (b) 3 months of age and injected with a quinpirole (300 μg/kg) assay of D 2 R function.
Accelerating rotarod test. The balance, motor coordination, and strength of mice were assessed using a motorized rotarod apparatus (Ugo Basile). For this test, mice underwent 2 consecutive days of training in which they were placed on a motorized rotarod that increased rotation speed from 4 to 40 rpm over a 5-minute period. For each training day, mice were provided 3 opportunities to maintain their perch on the rotarod as its speed increased. On the third day, the time it took the mice to fall from the beam was recorded. For this analysis, the 12-month-old RGS6 +/+ and RGS6 -/-mice were injected i.p. with saline, L-DOPA (25 mg/kg), or the GABA B receptor antagonist SCH-50911 (30 mg/kg) 20 minutes prior to testing.
Open-field test. Locomotor activity was assessed using an open-field test. For this test, mice were placed in an open-field box and were video recorded from above as they explored this novel environment for 10 minutes. The total distance traveled by each mouse was measured using these video recordings. To evaluate quinpirole suppression of locomotion, locomotor activity was measured for 15 minutes following i.p. injection with saline or quinpirole (300 μg/kg). EthoVision TX 11.5 software recorded the video and scored automatically for locomotor parameters.
DigiGait analysis. An automated treadmill gait analysis was performed using the DigiGait Imaging System (Mouse Specifics Inc.; refs. 26, 28) . For this analysis, mice were placed on a treadmill that was set at a fixed belt speed of 15 cm/s (a speed at which all aged animals were able to walk) and were video recorded using a camera mounted underneath the treadmill belt. The video recording was automatically processed by the DigiGait Imaging System software to calculate standard gait parameters. This test was used to analyze the gait of 12-month-old RGS6 +/+ and RGS6 -/-mice that received i.p. injections of either saline, L-DOPA (25 mg/kg), or the GABA B R antagonist SCH-50911 (30 mg/kg) 20 minutes prior to testing.
Immunohistochemistry. IHC analysis of RGS6 and TH expression was performed in both human and mouse SNc tissues. For these analyses, both human control and PD SNc containing midbrain sections were supplied by the Harvard Brain Tissue Resource Center via NIH NeuroBioBank Brain and Tissue Repositories. In preparation for the IHC analysis, mouse brain tissues were harvested from mice perfused with ice-cold saline followed by 4% paraformaldehyde. The whole brain was harvested and postfixed in 4% paraformaldehyde at 4°C overnight before being sunk in a 30% sucrose solution. Ten-micrometer coronal sections containing SNc were collected. Both human and mouse SNc tissue sections were placed in blocking/extraction solution (0.5% Triton X-100 and 10% goat serum in 1× PBS) for 1 hour at room temperature. After blocking, tissues were incubated overnight at 4°C in rabbit anti-RGS6 (homemade polyclonal antibody against the entire RGS6 protein 1:100, ref. 26) or mouse anti-TH (1:100; Millipore, MAB318). Additional IHC analysis of α-synuclein, phospho-PKA substrate, and pS40 TH was performed in mouse SNc tissues prepared as described previously using rabbit phospho-PKA substrate (1:100; Cell Signaling, 9621S), phosphoS40 TH (1:100; Cell Signaling, tutes of Health. The authors thank the NIH NeuroBioBank for providing PD and control human midbrain specimens. The authors also thank Michael J. Welsh (University of Iowa) for careful reading of and useful suggestions for this manuscript.
